SG10201606204TA - Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta - Google Patents
Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-BetaInfo
- Publication number
- SG10201606204TA SG10201606204TA SG10201606204TA SG10201606204TA SG10201606204TA SG 10201606204T A SG10201606204T A SG 10201606204TA SG 10201606204T A SG10201606204T A SG 10201606204TA SG 10201606204T A SG10201606204T A SG 10201606204TA SG 10201606204T A SG10201606204T A SG 10201606204TA
- Authority
- SG
- Singapore
- Prior art keywords
- laquinimod
- interferon
- beta
- treatment
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Packages (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161512817P | 2011-07-28 | 2011-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201606204TA true SG10201606204TA (en) | 2016-09-29 |
Family
ID=47597382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201606204TA SG10201606204TA (en) | 2011-07-28 | 2012-07-27 | Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta |
Country Status (16)
Country | Link |
---|---|
US (3) | US20130028866A1 (fr) |
EP (1) | EP2736336A4 (fr) |
JP (2) | JP2014521659A (fr) |
KR (1) | KR20140054129A (fr) |
CN (1) | CN103781355A (fr) |
AU (2) | AU2012286701A1 (fr) |
BR (1) | BR112014002092A2 (fr) |
CA (1) | CA2843432A1 (fr) |
EA (1) | EA201490378A1 (fr) |
HK (1) | HK1198278A1 (fr) |
MX (1) | MX2014001048A (fr) |
SG (1) | SG10201606204TA (fr) |
TW (1) | TW201726137A (fr) |
UY (1) | UY34359A (fr) |
WO (1) | WO2013016686A1 (fr) |
ZA (1) | ZA201401217B (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2600920T3 (es) | 2007-12-20 | 2017-02-13 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
EP2542079B1 (fr) | 2010-03-03 | 2014-05-21 | Teva Pharmaceutical Industries Ltd. | Traitement de la polyarthrite rhumatoïde au moyen d'une combinaison de laquinimod et de méthotrexate |
KR20130006640A (ko) * | 2010-03-03 | 2013-01-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
CN106344576A (zh) | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
EP2811832A4 (fr) | 2012-02-03 | 2015-09-23 | Teva Pharma | Utilisation de laquinimod pour le traitement de patients souffrant de la maladie de crohn pour lesquels la thérapie anti-tnf de première intention a échoué |
EP2744498A4 (fr) | 2012-02-16 | 2014-12-03 | Teva Pharma | N-éthyl-n-phényl -1,2-dihydro -4,5-di-hydroxy -1-méthyl -2-oxo -3-quinoléine carboxamide, sa préparation et son utilisation |
FR2988058B1 (fr) | 2012-03-15 | 2014-10-03 | A Fermetures As | Dispositif de calage a quai de vehicule de transport de marchandises |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
AR091706A1 (es) * | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
EA201590788A1 (ru) | 2012-11-07 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Аминные соли лахинимода |
CA2900503A1 (fr) * | 2013-02-15 | 2014-08-21 | Teva Pharmaceutical Industries Ltd. | Traitement de la sclerose en plaques a l'aide de laquinimod |
EA201591699A1 (ru) | 2013-03-14 | 2016-02-29 | Тева Фармасьютикал Индастриз Лтд. | Кристаллы лаквинимода натрия и улучшенный способ их производства |
WO2015017690A1 (fr) * | 2013-08-01 | 2015-02-05 | Teva Pharmaceutical Industries Ltd. | Traitement de la sclérose en plaques par induction à l'alemtuzumab suivie par une thérapie par laquinimod |
AU2015253330A1 (en) * | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
EP3303559A1 (fr) * | 2015-06-01 | 2018-04-11 | Biogen MA Inc. | Supplémentation en manganèse pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère |
US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
KR20080050591A (ko) * | 2005-09-01 | 2008-06-09 | 아레스 트레이딩 에스.에이. | 시신경염 치료 |
ATE532515T1 (de) * | 2006-06-12 | 2011-11-15 | Teva Pharma | Stabile laquinimod-zubereitungen |
US20110195049A1 (en) * | 2008-10-13 | 2011-08-11 | Biovista, Inc. | Compositions and methods for treating multiple sclerosis |
BR112012000568A2 (pt) * | 2009-06-19 | 2015-10-06 | Teva Pharma | tratamento da esclerose múltipla com laquinimod |
EP2455080A1 (fr) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | Agonistes de récepteur S1P1 à utiliser dans le traitement de la sclérose en plaques |
AU2015253330A1 (en) * | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
-
2012
- 2012-07-27 CN CN201280043782.6A patent/CN103781355A/zh active Pending
- 2012-07-27 SG SG10201606204TA patent/SG10201606204TA/en unknown
- 2012-07-27 AU AU2012286701A patent/AU2012286701A1/en not_active Abandoned
- 2012-07-27 US US13/560,872 patent/US20130028866A1/en not_active Abandoned
- 2012-07-27 EP EP12817547.8A patent/EP2736336A4/fr not_active Withdrawn
- 2012-07-27 EA EA201490378A patent/EA201490378A1/ru unknown
- 2012-07-27 BR BR112014002092A patent/BR112014002092A2/pt not_active IP Right Cessation
- 2012-07-27 MX MX2014001048A patent/MX2014001048A/es unknown
- 2012-07-27 JP JP2014523093A patent/JP2014521659A/ja not_active Withdrawn
- 2012-07-27 KR KR1020147004932A patent/KR20140054129A/ko not_active Application Discontinuation
- 2012-07-27 CA CA2843432A patent/CA2843432A1/fr not_active Abandoned
- 2012-07-27 WO PCT/US2012/048689 patent/WO2013016686A1/fr active Application Filing
- 2012-10-01 TW TW105134805A patent/TW201726137A/zh unknown
- 2012-10-01 UY UY0001034359A patent/UY34359A/es not_active Application Discontinuation
-
2014
- 2014-02-18 ZA ZA2014/01217A patent/ZA201401217B/en unknown
- 2014-10-29 US US14/527,199 patent/US20150056281A1/en not_active Abandoned
- 2014-11-21 HK HK14111811.8A patent/HK1198278A1/xx unknown
-
2016
- 2016-02-22 US US15/050,005 patent/US20160166648A1/en not_active Abandoned
- 2016-07-13 AU AU2016204909A patent/AU2016204909A1/en not_active Abandoned
- 2016-10-26 JP JP2016209185A patent/JP2017061482A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
NZ621215A (en) | 2015-11-27 |
US20160166648A1 (en) | 2016-06-16 |
HK1198278A1 (en) | 2015-03-27 |
KR20140054129A (ko) | 2014-05-08 |
AU2012286701A1 (en) | 2014-03-06 |
US20130028866A1 (en) | 2013-01-31 |
US20150056281A1 (en) | 2015-02-26 |
WO2013016686A1 (fr) | 2013-01-31 |
AU2016204909A1 (en) | 2016-08-04 |
EP2736336A4 (fr) | 2015-03-04 |
TW201726137A (zh) | 2017-08-01 |
CN103781355A (zh) | 2014-05-07 |
EA201490378A1 (ru) | 2014-07-30 |
JP2017061482A (ja) | 2017-03-30 |
CA2843432A1 (fr) | 2013-01-31 |
EP2736336A1 (fr) | 2014-06-04 |
JP2014521659A (ja) | 2014-08-28 |
ZA201401217B (en) | 2015-08-26 |
UY34359A (es) | 2014-02-28 |
MX2014001048A (es) | 2014-07-09 |
BR112014002092A2 (pt) | 2017-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201401217B (en) | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta | |
IL251397A0 (en) | Treatment of multiple sclerosis by administering a combination of laquinimod and glatiramer acetate | |
IL252699A0 (en) | Use of lequinimod to treat multiple sclerosis | |
HK1199820A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fingolimod | |
HK1205941A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
IL252547A0 (en) | Treatment of multiple sclerosis using laquinimod | |
HK1209672A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fampridine | |
HK1218254A1 (zh) | 用拉喹莫德治療多發性硬化症 | |
ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
EP2670406A4 (fr) | Thérapie combinée par un interféron et des andrographolides destinés à la sclérose en plaques | |
HK1223855A1 (zh) | 拉喹莫德和氟吡汀組合物用於治療多發性硬化症 | |
HK1227691A1 (zh) | 利用拉喹莫德和特立氟胺的組合來治療多發性硬化症 |